$34.10
-0.22[-0.64%]
At close: Apr 22
$34.10
0[0.00%]
After Hours: 4:00PM EDT
Inhibrx
(NASDAQ:INBX)Latest News for Inhibrx Stock (NASDAQ:INBX)
Inhibrx Stock (NASDAQ: INBX)
Categories: All
Wednesday, February 28, 2024
Tuesday, January 23, 2024
- Inhibrx shares are trading higher after the company announced the sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2 billion.Benzinga Newsdesk - Jan 23, 2024, 12:06PM
- French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2BVandana Singh - Jan 23, 2024, 8:00AM
- Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx ProjectBenzinga Neuro - Jan 23, 2024, 7:46AM
- JMP Securities Downgrades Inhibrx to Market PerformBenzinga Newsdesk - Jan 23, 2024, 4:34AM
- Inhibrx Sells INBRX-101 To Sanofi For Up To $2.2B, Spins Off New Company With All Non-101 Assets And LiabilitiesBenzinga Newsdesk - Jan 23, 2024, 1:09AM
Monday, November 20, 2023
Thursday, November 16, 2023
Thursday, November 09, 2023
Thursday, November 02, 2023
Tuesday, September 19, 2023
Thursday, August 31, 2023
Tuesday, August 29, 2023
- Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Aug 29, 2023, 12:51PM
- PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On TuesdayLisa Levin - Aug 29, 2023, 10:33AM
- Inhibrx Announces $200M Private Placement Financing; In The PIPE, Co Is Selling An Aggregate Of 3,621,314 Shares Of Its Common Stock At A Price Of $19.35 Per ShareHappy Mohamed - Aug 29, 2023, 9:03AM
Wednesday, August 23, 2023
Monday, August 07, 2023
Tuesday, May 30, 2023
Wednesday, May 10, 2023
Wednesday, April 26, 2023
Wednesday, March 08, 2023
Tuesday, March 07, 2023
Monday, March 06, 2023
Wednesday, January 04, 2023
Friday, November 18, 2022
Wednesday, November 16, 2022
- Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer CandidateVandana Singh - Nov 16, 2022, 10:42AM
- Inhibrx Announces Updated Efficacy And Safety Data From The Expansion Cohorts In The Phase 1 Trial Of INBRX-109 For The Treatment Of ChondrosarcomaBenzinga Newsdesk - Nov 16, 2022, 9:02AM
Tuesday, November 08, 2022
Monday, November 07, 2022
Thursday, October 13, 2022
Wednesday, October 05, 2022
Tuesday, October 04, 2022
- S&P 500 Rises 100 Points; Nasdaq Up 3%Lisa Levin - Oct 4, 2022, 2:49PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Oct 4, 2022, 1:53PM
- Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Oct 4, 2022, 12:41PM
- Nasdaq Surges 250 Points; Crude Oil Rises SharplyLisa Levin - Oct 4, 2022, 12:07PM
- US Stocks Open Higher As Dow Jumps 550 PointsLisa Levin - Oct 4, 2022, 9:58AM
- Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares SurgeVandana Singh - Oct 4, 2022, 9:28AM
- Inhibrx shares are trading higher after the company announced that, based on discussions with the FDA, there is potential to pursue an accelerated approval in the U.S. for INBRX-101.Benzinga Newsdesk - Oct 4, 2022, 8:33AM
- Inhibrx Says Based On FDA Discussions, There Is Potential To Pursue Accelerated Approval For INBRX-101Bill Haddad - Oct 4, 2022, 8:13AM
Monday, September 26, 2022
Monday, August 15, 2022
- Recap Of Monday's Biotech Catalysts - End Of the Day SummaryRagothaman Srinivasan - Aug 15, 2022, 6:58PM
- Inhibrx Secures European Commission Orphan Medicinal Product Designation For Bone Cancer CandidateRagothaman Srinivasan - Aug 15, 2022, 5:31PM
- Inhibrx Announces European Medicines Agency Grants Orphan Drug Designation To INBRX-109 For The Treatment Of ChondrosarcomaBenzinga Newsdesk - Aug 15, 2022, 4:32PM